Chicago Capital LLC Increases Stock Position in Boston Scientific Corporation $BSX

Chicago Capital LLC lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 17.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 585,159 shares of the medical equipment provider’s stock after purchasing an additional 87,168 shares during the quarter. Boston Scientific accounts for approximately 1.6% of Chicago Capital LLC’s holdings, making the stock its 25th biggest position. Chicago Capital LLC’s holdings in Boston Scientific were worth $62,852,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after purchasing an additional 3,932 shares during the last quarter. NS Partners Ltd raised its position in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after purchasing an additional 5,704 shares during the last quarter. Bank of New Hampshire raised its position in shares of Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after purchasing an additional 16,699 shares during the last quarter. MRA Advisory Group purchased a new position in shares of Boston Scientific in the 2nd quarter worth about $273,000. Finally, Neville Rodie & Shaw Inc. raised its position in shares of Boston Scientific by 95.9% in the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider’s stock worth $4,883,000 after purchasing an additional 22,255 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 1.3%

Shares of BSX stock opened at $96.89 on Tuesday. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock’s 50-day moving average price is $103.65 and its 200-day moving average price is $102.16. The stock has a market capitalization of $143.57 billion, a price-to-earnings ratio of 57.67, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business’s revenue was up 22.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 124,214 shares of company stock worth $13,048,957. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. UBS Group lifted their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Barclays lifted their price objective on Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a report on Friday, September 19th. Leerink Partners began coverage on Boston Scientific in a report on Monday, June 16th. They issued an “outperform” rating and a $118.00 price objective for the company. Finally, Raymond James Financial boosted their price target on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $118.38.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.